{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:13:45Z","timestamp":1770743625154,"version":"3.49.0"},"reference-count":189,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"am","delay-in-days":388,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.neurol.2024.02.385","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T15:27:06Z","timestamp":1709911626000},"page":"271-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug-resistant juvenile myoclonic epilepsy: A literature review"],"prefix":"10.1016","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6839-825X","authenticated-orcid":false,"given":"A.","family":"Nica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2024.02.385_bib0950","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.yebeh.2012.06.024","article-title":"Epidemiology of juvenile myoclonic epilepsy","volume":"28","author":"Camfield","year":"2013","journal-title":"Epilepsy Behav"},{"issue":"Suppl. 9","key":"10.1016\/j.neurol.2024.02.385_bib0955","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1167.2005.00309.x","article-title":"Epidemiology of idiopathic generalized epilepsies","volume":"46","author":"Jallon","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib0960","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/epi.13613","article-title":"Prevalence of juvenile myoclonic epilepsy in people\u00a0<\u00a030 years of age\u00a0\u2013\u00a0a population-based study in Norway","volume":"58","author":"Syvertsen","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib0965","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1600-0404.1985.tb00900.x","article-title":"Epilepsy with impulsive petit mal (juvenile myoclonic epilepsy)","volume":"72","author":"Janz","year":"1985","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurol.2024.02.385_bib0970","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1212\/WNL.34.3.285","article-title":"Juvenile myoclonic epilepsy of Janz","volume":"34","author":"Delgado-Escueta","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.02.385_bib0975","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eplepsyres.2015.11.012","article-title":"Pharmacological outcomes in juvenile myoclonic epilepsy: support for sodium valproate","volume":"119","author":"Chowdhury","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurol.2024.02.385_bib0980","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.seizure.2018.05.015","article-title":"Relapse after treatment withdrawal of antiepileptic drugs for juvenile absence epilepsy and juvenile myoclonic epilepsy","volume":"59","author":"Healy","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib0985","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/epi4.12603","article-title":"Recurrence rates and risk factors for seizure recurrence following antiseizure medication withdrawal in adolescent patients with genetic generalized epilepsy","volume":"7","author":"Komatsubara","year":"2022","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.neurol.2024.02.385_bib0990","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.seizure.2014.03.017","article-title":"Factors associated with lack of response to valproic acid monotherapy in juvenile myoclonic epilepsy","volume":"23","author":"Jayalakshmi","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib0995","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/ene.13811","article-title":"Refractory juvenile myoclonic epilepsy: a meta-analysis of prevalence and risk factors","volume":"26","author":"Stevelink","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1000","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/epi.17236","article-title":"ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Hirsch","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1005","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1093\/brain\/awl048","article-title":"Juvenile myoclonic epilepsy subsyndromes: family studies and long-term follow-up","volume":"129","author":"Mart\u00ednez-Ju\u00e1rez","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2024.02.385_bib1010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/seiz.2000.0432","article-title":"Characteristics of valproic acid resistant juvenile myoclonic epilepsy","volume":"9","author":"Fernando-Dongas","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1015","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/jnnp.70.2.240","article-title":"Clinical factors of drug resistance in juvenile myoclonic epilepsy","volume":"70","author":"Gelisse","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2024.02.385_bib1020","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/epi.13702","article-title":"Resistance to valproic acid as predictor of treatment resistance in genetic generalized epilepsies","volume":"58","author":"Gesche","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1025","doi-asserted-by":"crossref","first-page":"e2519","DOI":"10.1212\/WNL.0000000000010644","article-title":"Patterns and prognostic markers for treatment response in generalized epilepsies","volume":"95","author":"Gesche","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.02.385_bib1030","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1080\/14737175.2021.1931126","article-title":"Diagnostic and therapeutic approach to drug-resistant juvenile myoclonic epilepsy","volume":"21","author":"Ascoli","year":"2021","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.neurol.2024.02.385_bib1035","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.seizure.2021.08.019","article-title":"Treatment outcomes in drug resistant juvenile myoclonic epilepsy: valproate resistance may not be the end of the road","volume":"92","author":"Baheti","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1040","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/epi4.12349","article-title":"Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy","volume":"4","author":"Silvennoinen","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.neurol.2024.02.385_bib1045","series-title":"Filles, adolescentes, femmes en \u00e2ge de procr\u00e9er et femmes enceintes ayant une \u00e9pilepsie\u00a0: sp\u00e9cialit\u00e9s \u00e0 base de valproate et alternatives m\u00e9dicamenteuses","year":"2022"},{"key":"10.1016\/j.neurol.2024.02.385_bib1050","series-title":"EMA review of data on paternal exposure to valproate","year":"2023"},{"key":"10.1016\/j.neurol.2024.02.385_bib1055","series-title":"Information de s\u00e9curit\u00e9\u00a0\u2013\u00a0valproate et d\u00e9riv\u00e9s\u00a0: risque potentiel","year":"2023"},{"key":"10.1016\/j.neurol.2024.02.385_bib1060","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.yebeh.2013.01.002","article-title":"The history of juvenile myoclonic epilepsy","volume":"28","author":"Genton","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1065","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy","volume":"30","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1070","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1075","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1212\/WNL.47.4.912","article-title":"Long-term prognosis of typical childhood absence epilepsy: remission or progression to juvenile myoclonic epilepsy","volume":"47","author":"Wirrell","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.02.385_bib1080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41582-021-00583-9","article-title":"Genetic generalized epilepsies in adults\u00a0\u2013\u00a0challenging assumptions and dogmas","volume":"18","author":"Vorderw\u00fclbecke","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1085","doi-asserted-by":"crossref","first-page":"fcad182","DOI":"10.1093\/braincomms\/fcad182","article-title":"Variation in prognosis and treatment outcome in juvenile myoclonic epilepsy: a Biology of Juvenile Myoclonic Epilepsy Consortium proposal for a practical definition and stratified medicine classifications","volume":"5","author":"Rubboli","year":"2023","journal-title":"Brain Commun"},{"key":"10.1016\/j.neurol.2024.02.385_bib1090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.yebeh.2016.04.047","article-title":"High-dose versus low-dose valproate for the treatment of juvenile myoclonic epilepsy: going from low to high","volume":"61","author":"Hern\u00e1ndez-Vanegas","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1095","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.yebeh.2012.11.051","article-title":"Consensus on diagnosis and management of JME: from founder's observations to current trends","volume":"28","author":"Kasteleijn- Nolst Trenit\u00e9","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1100","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/j.1528-1167.2008.01859.x","article-title":"Differentiation of myoclonic seizures in epileptic syndromes: a video-polygraphic study of 26 patients","volume":"50","author":"Hirano","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1105","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1528-1157.1994.tb02435.x","article-title":"Video-polygraphic analysis of myoclonic seizures in juvenile myoclonic epilepsy","volume":"35","author":"Oguni","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1110","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.yebeh.2012.11.042","article-title":"Neurophysiology of juvenile myoclonic epilepsy","volume":"28","author":"Serafini","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1115","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.yebeh.2012.10.034","article-title":"Clinical aspects of juvenile myoclonic epilepsy","volume":"28","author":"Genton","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1120","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1212\/01.wnl.0000313148.34629.1d","article-title":"Myoclonic seizures subside in the fourth decade in juvenile myoclonic epilepsy","volume":"70","author":"Baykan","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.02.385_bib1125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.eplepsyres.2015.04.008","article-title":"Juvenile myoclonic epilepsy: a system disorder of the brain","volume":"114","author":"Wolf","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurol.2024.02.385_bib1130","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/seiz.1999.0376","article-title":"Photosensitivity in juvenile myoclonic epilepsy","volume":"9","author":"Appleton","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1135","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1684\/epd.2020.1192","article-title":"How to diagnose and classify idiopathic (genetic) generalized epilepsies","volume":"22","author":"Elmali","year":"2020","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.neurol.2024.02.385_bib1140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.yebeh.2004.01.007","article-title":"Cognitive function in juvenile myoclonic epilepsy","volume":"5","author":"Sonmez","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1145","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1111\/epi.12003","article-title":"Frontal lobe function and structure in juvenile myoclonic epilepsy: a comprehensive review of neuropsychological and imaging data","volume":"53","author":"Wandschneider","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1150","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00415-012-6715-z","article-title":"Decision making in juvenile myoclonic epilepsy","volume":"260","author":"Zamarian","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1155","doi-asserted-by":"crossref","first-page":"108633","DOI":"10.1016\/j.yebeh.2022.108633","article-title":"Pseudoresistance in idiopathic\/genetic generalized epilepsies\u00a0\u2013\u00a0Definitions, risk factors, and outcome","volume":"130","author":"Gesche","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1160","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1165","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.yebeh.2017.10.024","article-title":"The \u201cCinderella syndrome\u201d: a narrative study of social curfews and lifestyle restrictions in juvenile myoclonic epilepsy","volume":"78","author":"Leahy","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1170","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cnp.2022.09.003","article-title":"Myoclonus and other jerky movement disorders","volume":"7","author":"Van Der Veen","year":"2022","journal-title":"Clin Neurophysiol Pract"},{"key":"10.1016\/j.neurol.2024.02.385_bib1175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.seizure.2018.07.014","article-title":"Nationwide survey in Japan endorsed diagnostic criteria of benign adult familial myoclonus epilepsy","volume":"61","author":"Kobayashi","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1180","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.seizure.2019.03.009","article-title":"Familial adult myoclonic epilepsy: a new expansion repeats disorder","volume":"67","author":"Lagorio","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1185","first-page":"174","article-title":"Familial adult myoclonic epilepsy: clinical and genetic approach to an under-recognized disease","volume":"60","author":"Altiokka Uzun","year":"2023","journal-title":"Arch Neuropsychiatry"},{"key":"10.1016\/j.neurol.2024.02.385_bib1190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1684\/epd.2016.0847","article-title":"Progressive myoclonus epilepsy associated with neuroserpin inclusion bodies (neuroserpinosis)","volume":"18","author":"Roussel","year":"2016","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.neurol.2024.02.385_bib1195","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.seizure.2019.08.012","article-title":"The best evidence for progressive myoclonic epilepsy: a pathway to precision therapy","volume":"71","author":"Orsini","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1200","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.seizure.2019.04.016","article-title":"A very rare form of autosomal dominant progressive myoclonus epilepsy caused by a novel variant in the PRICKLE1 gene","volume":"69","author":"Algahtani","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1205","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41582-018-0101-0","article-title":"POLG-related disorders and their neurological manifestations","volume":"15","author":"Rahman","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1210","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1684\/epd.2016.0859","article-title":"Myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK) is caused by heterozygous KCNC1 mutations","volume":"18","author":"Nascimento","year":"2016","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.neurol.2024.02.385_bib1215","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yebeh.2018.03.002","article-title":"Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral center","volume":"82","author":"Ca\u00e7\u00e3o","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1220","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.seizure.2021.01.005","article-title":"Long-term prognosis of juvenile myoclonic epilepsy: a systematic review searching for sex differences","volume":"86","author":"Giuliano","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1225","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1111\/epi.17410","article-title":"Drug resistance in idiopathic generalized epilepsies: evidence and concepts","volume":"63","author":"Gesche","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1230","first-page":"101732","article-title":"Individualised prediction of drug resistance and seizure recurrence after medication withdrawal in people with juvenile myoclonic epilepsy: a systematic review and individual participant data meta-analysis","volume":"53","author":"Stevelink","year":"2022","journal-title":"eClin Med"},{"key":"10.1016\/j.neurol.2024.02.385_bib1235","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.yebeh.2007.03.008","article-title":"Juvenile myoclonic epilepsy: a benign disorder? Personality traits and psychiatric symptoms","volume":"10","author":"Plattner","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1240","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.yebeh.2013.03.026","article-title":"Juvenile myoclonic epilepsy: psychiatric comorbidity and impact on outcome","volume":"28","author":"De Araujo Filho","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1245","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pediatrneurol.2019.03.011","article-title":"The timing, nature, and range of neurobehavioral comorbidities in juvenile myoclonic epilepsy","volume":"101","author":"Almane","year":"2019","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1250","doi-asserted-by":"crossref","first-page":"109216","DOI":"10.1016\/j.yebeh.2023.109216","article-title":"Prevalence, nature, and severity of the psychiatric comorbidities and their impact on quality of life in adolescents with juvenile myoclonic epilepsy","volume":"142","author":"Panda","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1255","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/epi.13061","article-title":"Neuropsychological profiles of patients with juvenile myoclonic epilepsy and their siblings: an extended study","volume":"56","author":"Iqbal","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1260","doi-asserted-by":"crossref","first-page":"109204","DOI":"10.1016\/j.yebeh.2023.109204","article-title":"Neurocognitive profile in patients with idiopathic generalized epilepsies: differences between patients, their biological siblings, and healthy controls","volume":"142","author":"Javurkova","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1265","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181b9c86f","article-title":"Juvenile myoclonic epilepsy 25 years after seizure onset: a population-based study","volume":"73","author":"Camfield","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.02.385_bib1270","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1528-1157.1994.tb02434.x","article-title":"Clinical and EEG asymmetries in juvenile myoclonic epilepsy","volume":"35","author":"Lancman","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1275","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1017\/S0317167100051519","article-title":"Epileptiform asymetries and treatment response in juvenile myoclonic epilepsy","volume":"37","author":"L\u00e9tourneau","year":"2010","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.neurol.2024.02.385_bib1280","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1528-1167.2011.03352.x","article-title":"Enhanced frontocentral EEG connectivity in photosensitive generalized epilepsies: a partial directed coherence study","volume":"53","author":"Varotto","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1285","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/brain\/awg109","article-title":"Gamma-band phase clustering and photosensitivity: is there an underlying mechanism common to photosensitive epilepsy and visual perception?","volume":"126","author":"Parra","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2024.02.385_bib1290","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.neuroimage.2009.07.019","article-title":"fMRI activation during spike and wave discharges evoked by photic stimulation","volume":"48","author":"Moeller","year":"2009","journal-title":"NeuroImage"},{"key":"10.1016\/j.neurol.2024.02.385_bib1295","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.yebeh.2013.02.010","article-title":"Visual cortex hyperexcitability in idiopathic generalized epilepsies with photosensitivity: a TMS pilot study","volume":"27","author":"Brigo","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1300","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1038\/s41598-022-06324-2","article-title":"Sex-specific disease modifiers in juvenile myoclonic epilepsy","volume":"12","author":"Shakeshaft","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurol.2024.02.385_bib1305","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/epi.16467","article-title":"Testing association of rare genetic variants with resistance to three common antiseizure medications","volume":"61","author":"Wolking","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1310","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/epi.12151","article-title":"Patterns of cortical hyperexcitability in adolescent\/adult-onset generalized epilepsies","volume":"54","author":"Badawy","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1315","doi-asserted-by":"crossref","first-page":"1250030","DOI":"10.1142\/S012906571250030X","article-title":"Cortical excitability and refractory epilepsy: a three-year longitudinal transcranial magnetic stimulation study","volume":"23","author":"Badawy","year":"2013","journal-title":"Int J Neural Syst"},{"key":"10.1016\/j.neurol.2024.02.385_bib1320","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.eplepsyres.2013.11.014","article-title":"TMS, cortical excitability and epilepsy: the clinical impact","volume":"108","author":"Badawy","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurol.2024.02.385_bib1325","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.clinph.2021.02.405","article-title":"Magnetic evoked potential polyphasia in idiopathic\/genetic generalized epilepsy: an endophenotype not associated with treatment response","volume":"132","author":"Gesche","year":"2021","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1330","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/brain\/awr098","article-title":"Motor system hyperconnectivity in juvenile myoclonic epilepsy: a cognitive functional magnetic resonance imaging study","volume":"134","author":"Vollmar","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2024.02.385_bib1335","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.0b013e3182563b44","article-title":"Altered microstructural connectivity in juvenile myoclonic epilepsy: the missing link","volume":"78","author":"Vollmar","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.02.385_bib1340","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1093\/brain\/awu175","article-title":"Motor co-activation in siblings of patients with juvenile myoclonic epilepsy: an imaging endophenotype?","volume":"137","author":"Wandschneider","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2024.02.385_bib1345","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.nicl.2014.11.018","article-title":"Hyperconnectivity in juvenile myoclonic epilepsy: a network analysis","volume":"7","author":"Caeyenberghs","year":"2015","journal-title":"NeuroImage Clin"},{"key":"10.1016\/j.neurol.2024.02.385_bib1350","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s11682-021-00595-5","article-title":"A systematic review of resting-state and task-based fMRI in juvenile myoclonic epilepsy","volume":"16","author":"Sanjari Moghaddam","year":"2022","journal-title":"Brain Imaging Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1355","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3390\/brainsci12121658","article-title":"Altered cerebro-cerebellar effective connectivity in new-onset juvenile myoclonic epilepsy","volume":"12","author":"Ma","year":"2022","journal-title":"Brain Sci"},{"key":"10.1016\/j.neurol.2024.02.385_bib1360","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1528-1157.1985.tb05665.x","article-title":"The significance of microdysgenesia in primary generalized epilepsy: an answer to the considerations of Lyon and Gastaut","volume":"26","author":"Meencke","year":"1985","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1365","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1212\/WNL.55.8.1101","article-title":"Idiopathic generalized epilepsy: lack of significant microdysgenesis","volume":"55","author":"Opeskin","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.02.385_bib1370","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3390\/medicina57111136","article-title":"Gray matter changes in juvenile myoclonic epilepsy. A voxel-wise meta-analysis","volume":"57","author":"Kazis","year":"2021","journal-title":"Medicina"},{"key":"10.1016\/j.neurol.2024.02.385_bib1375","doi-asserted-by":"crossref","first-page":"883078","DOI":"10.3389\/fneur.2022.883078","article-title":"Correlations between structural brain abnormalities, cognition and electroclinical characteristics in patients with juvenile myoclonic epilepsy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1380","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/brain\/awz215","article-title":"Abnormal hippocampal structure and function in juvenile myoclonic epilepsy and unaffected siblings","volume":"142","author":"Caciagli","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2024.02.385_bib1385","doi-asserted-by":"crossref","first-page":"fcab196","DOI":"10.1093\/braincomms\/fcab196","article-title":"Functional network topology in drug resistant and well-controlled idiopathic generalized epilepsy: a resting state functional MRI study","volume":"3","author":"Pegg","year":"2021","journal-title":"Brain Commun"},{"key":"10.1016\/j.neurol.2024.02.385_bib1390","doi-asserted-by":"crossref","first-page":"109282","DOI":"10.1016\/j.jneumeth.2021.109282","article-title":"A convolutional-recurrent neural network approach to resting-state EEG classification in Parkinson's disease","volume":"361","author":"Lee","year":"2021","journal-title":"J Neurosci Meth"},{"key":"10.1016\/j.neurol.2024.02.385_bib1395","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/brain.2021.0035","article-title":"Altered structural brain networks in refractory and nonrefractory idiopathic generalized epilepsy","volume":"12","author":"McKavanagh","year":"2022","journal-title":"Brain Connect"},{"key":"10.1016\/j.neurol.2024.02.385_bib1400","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.yebeh.2012.06.036","article-title":"Lifetime prognosis of juvenile myoclonic epilepsy","volume":"28","author":"Baykan","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1405","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/epi.12062","article-title":"The relationship between the localization of the generalized spike and wave discharge generators and the response to valproate","volume":"54","author":"Szaflarski","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1410","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2217\/pgs-2019-0179","article-title":"Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study","volume":"21","author":"Wolking","year":"2020","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.neurol.2024.02.385_bib1415","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2024.02.385_bib1420","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2024.02.385_bib1425","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.eplepsyres.2017.07.018","article-title":"Efficacy of a third or later antiepileptic drug regimen according to epilepsy syndrome among adult patients","volume":"136","author":"Ito","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurol.2024.02.385_bib1430","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/epi4.12321","article-title":"Clinical features and treatment outcomes of juvenile myoclonic epilepsy patients","volume":"4","author":"Zhang","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.neurol.2024.02.385_bib1435","doi-asserted-by":"crossref","first-page":"107746","DOI":"10.1016\/j.yebeh.2020.107746","article-title":"Adjunctive brivaracetam\u00a0\u2013\u00a0a prospective audit of outcomes from an epilepsy clinic","volume":"116","author":"Stephen","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1440","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1007\/s00415-023-11834-8","article-title":"Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis","volume":"270","author":"Chu","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1445","first-page":"1","article-title":"Topiramate for juvenile myoclonic epilepsy","volume":"2021","author":"Liu","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2024.02.385_bib1450","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/WNL.54.1.230","article-title":"Valproate-induced hyperammonemic encephalopathy in the presence of topiramate","volume":"54","author":"Hamer","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.02.385_bib1455","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hup.575","article-title":"Drug induced encephalopathy in six epileptic patients: topiramate? Valproate? Or both?","volume":"19","author":"Latour","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1460","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4212\/cjhp.v68i1.1425","article-title":"Encephalopathy induced by combination therapy with valproic acid and topiramate: challenging the utility of serum ammonia measurement","volume":"68","author":"Sin","year":"2015","journal-title":"CJHP"},{"key":"10.1016\/j.neurol.2024.02.385_bib1465","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamaneurol.2022.1269","article-title":"Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability","volume":"79","author":"Bj\u00f8rk","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1470","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.seizure.2022.05.005","article-title":"Trends in the choice of antiseizure medications in juvenile myoclonic epilepsy: a retrospective multi-center study from Turkey between 2010 and 2020","volume":"99","author":"K\u0131l\u0131\u00e7","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1475","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.seizure.2013.07.006","article-title":"Efficacy and tolerability of lamotrigine in juvenile myoclonic epilepsy in adults: a prospective, unblinded randomized controlled trial","volume":"22","author":"Machado","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1480","doi-asserted-by":"crossref","first-page":"107706","DOI":"10.1016\/j.yebeh.2020.107706","article-title":"Response to levetiracetam or lamotrigine in subjects with juvenile myoclonic epilepsy previously treated with valproic acid: a single center retrospective study","volume":"115","author":"Milano","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1485","first-page":"617","article-title":"Efficacy of levetiracetam, lamotrigine and sodium valproate on seizure attacks and EEG disorders in patients with juvenile myoclonic epilepsy: a double blind randomized clinical trial","volume":"13","author":"Daneshyar","year":"2022","journal-title":"Caspian J Intern Med"},{"key":"10.1016\/j.neurol.2024.02.385_bib1490","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1212\/WNL.55.11.1757","article-title":"Exacerbation of juvenile myoclonic epilepsy with lamotrigine","volume":"55","author":"Biraben","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.02.385_bib1495","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1212\/WNL.56.10.1424-a","article-title":"Exacerbation of juvenile myoclonic epilepsy with lamotrigine","volume":"56","author":"Carrazana","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.02.385_bib1500","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/01.wnl.0000174517.21383.36","article-title":"Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies","volume":"65","author":"Crespel","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.02.385_bib1505","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40263-018-00602-2","article-title":"Treatment of juvenile myoclonic epilepsy in patients of child-bearing potential","volume":"33","author":"Serafini","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurol.2024.02.385_bib1510","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/17512433.2021.1959317","article-title":"Therapeutic approach to difficult-to-treat typical absences and related epilepsy syndromes","volume":"14","author":"Mastroianni","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1515","doi-asserted-by":"crossref","first-page":"106657","DOI":"10.1016\/j.yebeh.2019.106657","article-title":"Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy","volume":"102","author":"Fonseca","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1520","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.02.385_bib1525","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1684\/epd.2022.1439","article-title":"A systematic review of the efficacy of perampanel as treatment for myoclonic seizures and symptomatic myoclonus","volume":"24","author":"Mir","year":"2022","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.neurol.2024.02.385_bib1530","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.seizure.2022.06.008","article-title":"Perampanel for the treatment of patients with myoclonic seizures in clinical practice: evidence from the PERMIT study","volume":"100","author":"D'Souza","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1535","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2016.12.015","article-title":"Lacosamide for uncontrolled primary generalized tonic-clonic seizures: an open-label pilot study with 59-week extension","volume":"130","author":"Wechsler","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurol.2024.02.385_bib1540","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ebcr.2017.08.001","article-title":"Lacosamide for refractory generalized tonic\u2013clonic seizures of non-focal origin in clinical practice: a clinical and VEEG study","volume":"8","author":"Abarrategui","year":"2017","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.neurol.2024.02.385_bib1545","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ebcr.2016.09.006","article-title":"Unmasking of myoclonus by lacosamide in generalized epilepsy","volume":"7","author":"Birnbaum","year":"2017","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.neurol.2024.02.385_bib1550","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.braindev.2023.05.007","article-title":"Two-year efficacy of lacosamide as adjunctive therapy for generalized tonic-clonic seizures in patients with juvenile myoclonic epilepsy","volume":"45","author":"Kobayashi","year":"2023","journal-title":"Brain Dev"},{"key":"10.1016\/j.neurol.2024.02.385_bib1555","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1684\/epd.2019.1032","article-title":"Absence status induced by lacosamide adjunctive therapy","volume":"21","author":"Szab\u00f3","year":"2019","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.neurol.2024.02.385_bib1560","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/epi.16306","article-title":"Cortical activation in generalized seizures","volume":"60","author":"Ding","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1565","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.clinph.2022.02.024","article-title":"Network connectivity in primary generalized tonic-clonic seizures","volume":"138","author":"McGuinness","year":"2022","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1570","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/brain\/awy223","article-title":"Dynamic brain network states in human generalized spike-wave discharges","volume":"141","author":"Tangwiriyasakul","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2024.02.385_bib1575","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/brain\/awaa072","article-title":"Clinical and experimental insight into pathophysiology, comorbidity and therapy of absence seizures","volume":"143","author":"Crunelli","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2024.02.385_bib1580","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-0404.2007.00848.x","article-title":"Is vagus nerve stimulation a treatment option for patients with drug-resistant idiopathic generalized epilepsy?","volume":"115","author":"Kostov","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurol.2024.02.385_bib1585","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.eplepsyres.2019.02.004","article-title":"30 years of vagus nerve stimulation trials in epilepsy: do we need neuromodulation-specific trial designs?","volume":"153","author":"Dibu\u00e9-Adjei","year":"2019","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurol.2024.02.385_bib1590","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.brainresbull.2008.09.016","article-title":"The primate centromedian-parafascicular complex: anatomical organization with a note on neuromodulation","volume":"78","author":"Sadikot","year":"2009","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.neurol.2024.02.385_bib1595","doi-asserted-by":"crossref","first-page":"fcad003","DOI":"10.1093\/braincomms\/fcad003","article-title":"The intralaminar thalamus: a review of its role as a target in functional neurosurgery","volume":"5","author":"Arnts","year":"2023","journal-title":"Brain Commun"},{"key":"10.1016\/j.neurol.2024.02.385_bib1600","series-title":"Diencephalon: ventral thalamus or subthalamus. The human central nervous system","first-page":"281","year":"2008"},{"key":"10.1016\/j.neurol.2024.02.385_bib1605","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s13311-021-01057-y","article-title":"Network substrates of centromedian nucleus deep brain stimulation in generalized pharmacoresistant epilepsy","volume":"18","author":"Torres Diaz","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurol.2024.02.385_bib1610","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1111\/epi.17272","article-title":"Response: deep brain stimulation targets in epilepsy: systematic review and meta-analysis of anterior and centromedian thalamic nuclei and hippocampus","volume":"63","author":"Vetkas","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1615","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/epi.12352","article-title":"Deep brain stimulation of the centromedian thalamic nucleus for the treatment of generalized and frontal epilepsies","volume":"54","author":"Valent\u00edn","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1620","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/jnnp-2021-327512","article-title":"Responsive neurostimulation of the thalamus improves seizure control in idiopathic generalised epilepsy: initial case series","volume":"93","author":"Sisterson","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2024.02.385_bib1625","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.seizure.2010.10.004","article-title":"Prognosis of juvenile myoclonic epilepsy is related to endophenotypes","volume":"20","author":"Guaranha","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1630","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eplepsyres.2017.01.011","article-title":"Prognostic factors in patients with refractory idiopathic generalized epilepsy","volume":"130","author":"Gomez-Iba\u00f1ez","year":"2017","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.neurol.2024.02.385_bib1635","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2147\/RMHP.S244725","article-title":"Predictors of outcome in juvenile myoclonic epilepsy","volume":"13","author":"Chen","year":"2020","journal-title":"RMHP"},{"key":"10.1016\/j.neurol.2024.02.385_bib1640","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.neurol.2020.03.018","article-title":"Genetic\/idiopathic generalized epilepsies: not so good as that!","volume":"176","author":"Nilo","year":"2020","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2024.02.385_bib1645","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/ane.13556","article-title":"Seizure outcome trajectories in a well-defined cohort of newly diagnosed juvenile myoclonic epilepsy patients","volume":"145","author":"Cerulli Irelli","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurol.2024.02.385_bib1650","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.seizure.2021.11.019","article-title":"High rates of early remission pattern in adult-onset compared with earlier-onset idiopathic generalized epilepsy: a long-term follow-up study","volume":"94","author":"Cerulli Irelli","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1655","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1600-0404.2006.00791.x","article-title":"Outcomes of newly diagnosed idiopathic generalized epilepsy syndromes in a non-pediatric setting","volume":"115","author":"Mohanraj","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurol.2024.02.385_bib1660","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1111\/epi.16708","article-title":"Persistent treatment resistance in genetic generalized epilepsy: a long-term outcome study in a tertiary epilepsy center","volume":"61","author":"Cerulli Irelli","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1665","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/epi.13761","article-title":"Long-term outcome in adolescent-onset generalized genetic epilepsies","volume":"58","author":"Vorderw\u00fclbecke","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1670","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1111\/j.1528-1167.2012.03723.x","article-title":"The prognosis of idiopathic generalized epilepsy","volume":"53","author":"Seneviratne","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1675","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.seizure.2019.06.021","article-title":"Outcomes of low-dose valproic acid treatment in patients with juvenile myoclonic epilepsy","volume":"70","author":"G\u00fcrer","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1680","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.seizure.2020.06.033","article-title":"Seizure control and anxiety: which factor plays a major role in social adjustment in patients with juvenile myoclonic epilepsy?","volume":"80","author":"Paiva","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1685","doi-asserted-by":"crossref","first-page":"e2150","DOI":"10.1212\/WNL.0000000000010597","article-title":"Development and validation of a predictive model of drug-resistant genetic generalized epilepsy","volume":"95","author":"Choi","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.02.385_bib1690","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.braindev.2021.02.005","article-title":"Juvenile myoclonic epilepsy: long-term prognosis and risk factors","volume":"43","author":"Pietrafusa","year":"2021","journal-title":"Brain Dev"},{"key":"10.1016\/j.neurol.2024.02.385_bib1695","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.seizure.2023.04.021","article-title":"Neuropsychological profile and drug treatment response in idiopathic generalized epilepsy","volume":"109","author":"Jeppesen","year":"2023","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1700","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.yebeh.2010.02.005","article-title":"Seizure control in patients with idiopathic generalized epilepsies: EEG determinants of medication response","volume":"17","author":"Szaflarski","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1705","first-page":"2128","article-title":"Prognosis of juvenile myoclonic epilepsy 45 years after onset: seizure outcome and predictors","volume":"81","author":"Senf","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.02.385_bib1710","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/ene.14142","article-title":"Epidemiology and outcome of idiopathic generalized epilepsy in adults","volume":"27","author":"Gesche","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1715","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1528-1167.2012.03526.x","article-title":"Predictors for long-term seizure outcome in juvenile myoclonic epilepsy: 25\u201363 years of follow-up","volume":"53","author":"Geithner","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1720","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.eplepsyres.2014.04.004","article-title":"Natural course and predictors of spontaneous seizure remission in idiopathic generalized epilepsy: 7\u201327 years of follow-up","volume":"108","author":"von Podewils","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurol.2024.02.385_bib1725","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.eplepsyres.2014.09.008","article-title":"Seizure outcome in 175 patients with juvenile myoclonic epilepsy\u00a0\u2013\u00a0a long-term observational study","volume":"108","author":"H\u00f6fler","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurol.2024.02.385_bib1730","doi-asserted-by":"crossref","first-page":"e1822","DOI":"10.1212\/WNL.0000000000006472","article-title":"Generalized polyspike train: an EEG biomarker of drug-resistant idiopathic generalized epilepsy","volume":"91","author":"Sun","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.02.385_bib1735","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/epi.17104","article-title":"Clinical and EEG factors associated with antiseizure medication resistance in idiopathic generalized epilepsy","volume":"63","author":"Kamitaki","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1740","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1059-1311(05)80097-4","article-title":"Characterization of intractable juvenile myoclonic epilepsy: new perspectives on primarily generalized seizures","volume":"2","author":"Dasheiff","year":"1993","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1745","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1212\/CPJ.0000000000000323","article-title":"EEG correlates of seizure freedom in genetic generalized epilepsies","volume":"7","author":"Seneviratne","year":"2017","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.neurol.2024.02.385_bib1750","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eplepsyres.2017.05.003","article-title":"Prolonged epileptiform EEG runs are associated with persistent seizures in juvenile myoclonic epilepsy","volume":"134","author":"Arntsen","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurol.2024.02.385_bib1755","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clinph.2013.07.028","article-title":"Prognostic value of EEG asymmetries for development of drug-resistance in drug-na\u00efve patients with genetic generalized epilepsies","volume":"125","author":"Karakis","year":"2014","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1760","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.clinph.2015.11.048","article-title":"Focal EEG features and therapeutic response in patients with juvenile absence and myoclonic epilepsy","volume":"127","author":"Japaridze","year":"2016","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1765","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.3390\/biomedicines10102428","article-title":"EEG markers of treatment resistance in idiopathic generalized epilepsy: from standard EEG findings to advanced signal analysis","volume":"10","author":"Cerulli Irelli","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.neurol.2024.02.385_bib1770","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/WNP.0000000000000679","article-title":"Prognostic value of generalized polyspike trains and prolonged epileptiform EEG runs","volume":"38","author":"Jensen","year":"2021","journal-title":"J Clin Neurophysiol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1775","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/epi.16875","article-title":"Prolonged epileptic discharges predict seizure recurrence in JME: insights from prolonged ambulatory EEG","volume":"62","author":"Turco","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1780","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/WNP.0000000000000803","article-title":"Using generalized polyspike train to predict drug-resistant idiopathic generalized epilepsy","volume":"39","author":"Conrad","year":"2022","journal-title":"J Clin Neurophysiol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1785","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.seizure.2013.07.008","article-title":"Eye closure sensitivity in juvenile myoclonic epilepsy and its effect on prognosis","volume":"22","author":"Tekin G\u00fcveli","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1790","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.seizure.2018.09.006","article-title":"Prognosis of juvenile myoclonic epilepsy with eye-closure sensitivity","volume":"62","author":"Uchida","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1795","doi-asserted-by":"crossref","first-page":"107427","DOI":"10.1016\/j.yebeh.2020.107427","article-title":"Spectral power of interictal EEG in the diagnosis and prognosis of idiopathic generalized epilepsies","volume":"112","author":"Pegg","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1800","doi-asserted-by":"crossref","first-page":"106119","DOI":"10.1016\/j.clineuro.2020.106119","article-title":"Can we predict drug response by functional connectivity in patients with juvenile myoclonic epilepsy?","volume":"198","author":"Kim","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.neurol.2024.02.385_bib1805","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2217\/pgs.09.32","article-title":"Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese","volume":"10","author":"Kwan","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.neurol.2024.02.385_bib1810","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/FPC.0000000000000000","article-title":"GABRG2, rs211037 is associated with epilepsy susceptibility, but not with antiepileptic drug resistance and febrile seizures","volume":"23","author":"Balan","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.neurol.2024.02.385_bib1815","doi-asserted-by":"crossref","first-page":"e89253","DOI":"10.1371\/journal.pone.0089253","article-title":"Genetic association analysis of ATP binding cassette protein family reveals a novel association of ABCB1 genetic variants with epilepsy risk, but not with drug-resistance","volume":"9","author":"Balan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2024.02.385_bib1820","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/cns.12169","article-title":"Gene-wide tagging study of the association between KCNT1 polymorphisms and the susceptibility and efficacy of genetic generalized epilepsy in Chinese population","volume":"20","author":"Qu","year":"2014","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.neurol.2024.02.385_bib1825","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jns.2015.04.045","article-title":"Common variants of ATP1A3 but not ATP1A2 are associated with Chinese genetic generalized epilepsies","volume":"354","author":"Qu","year":"2015","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2024.02.385_bib1830","doi-asserted-by":"crossref","first-page":"e0124896","DOI":"10.1371\/journal.pone.0124896","article-title":"Common variants of KCNJ10 are associated with susceptibility and anti-epileptic drug resistance in Chinese genetic generalized epilepsies","volume":"10","author":"Guo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2024.02.385_bib1835","doi-asserted-by":"crossref","first-page":"e7321","DOI":"10.1097\/MD.0000000000007321","article-title":"Pharmacogenetic and case-control study on potassium channel related gene variants and genetic generalized epilepsy","volume":"96","author":"Qu","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.neurol.2024.02.385_bib1840","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/1440-1681.12877","article-title":"Case-control pharmacogenetic study of HCN1\/HCN2 variants and genetic generalized epilepsies","volume":"45","author":"Wu","year":"2018","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.neurol.2024.02.385_bib1845","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.yebeh.2018.10.026","article-title":"Cortical excitability and seizure control influence attention performance in patients with idiopathic generalized epilepsies (IGEs)","volume":"89","author":"Bolden","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2024.02.385_bib1850","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/epi.12057","article-title":"Reduced default mode network connectivity in treatment-resistant idiopathic generalized epilepsy","volume":"54","author":"Kay","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1855","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/epi.12486","article-title":"Differences in paracingulate connectivity associated with epileptiform discharges and uncontrolled seizures in genetic generalized epilepsy","volume":"55","author":"Kay","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2024.02.385_bib1860","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.12659\/MSM.897002","article-title":"White matter abnormalities in patients with treatment-resistant genetic generalized epilepsies","volume":"22","author":"Szaflarski","year":"2016","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.neurol.2024.02.385_bib1865","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.seizure.2018.09.015","article-title":"Analysis of fractional anisotropy and mean diffusivity in refractory and non-refractory idiopathic generalized epilepsies","volume":"62","author":"Lobato","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1870","doi-asserted-by":"crossref","first-page":"103474","DOI":"10.1016\/j.nicl.2023.103474","article-title":"Multi-spectral diffusion MRI mega-analysis in genetic generalized epilepsy: relation to outcomes","volume":"39","author":"Kreilkamp","year":"2023","journal-title":"NeuroImage Clin"},{"key":"10.1016\/j.neurol.2024.02.385_bib1875","first-page":"75","article-title":"The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies","volume":"1","author":"Nicolson","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2024.02.385_bib1880","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.seizure.2014.08.004","article-title":"Predictors of seizure control in patients with juvenile myoclonic epilepsy (JME)","volume":"23","author":"Asadi-Pooya","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2024.02.385_bib1885","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1472-6963-8-264","article-title":"Seizure control in patients with epilepsy: the physician vs. medication factors","volume":"8","author":"Szaflarski","year":"2008","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.neurol.2024.02.385_bib1890","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1111\/epi.14454","article-title":"Long-term negative impact of an inappropriate first antiepileptic medication on the efficacy of a second antiepileptic medication in mice","volume":"59","author":"Pawluski","year":"2018","journal-title":"Epilepsia"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724004223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724004223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T12:46:43Z","timestamp":1713962803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378724004223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":189,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0035378724004223"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2024.02.385","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-resistant juvenile myoclonic epilepsy: A literature review","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2024.02.385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}